nonalcoholic%20fatty%20liver%20disease
NONALCOHOLIC FATTY LIVER DISEASE
Treatment Guideline Chart

Nonalcoholic fatty liver disease is having excessive hepatic fat (in the form of triglycerides) accumulation not due to excessive alcohol consumption or other secondary causes.

It is considered as a hepatic manifestation of metabolic syndrome.

Progression of nonalcoholic fatty liver disease is variable.

Nonalcoholic Fatty Liver Disease References

  1. Chalasani N, Younossi Z, Lavine JE, et al. The diagnosis and management of non-alcoholic fatty liver disease: practice guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Association. Hepatology. 2012 Jun;55(6):2005-2023. doi: 10.1002/hep.25762. PMID: 22488764
  2. European Association for the Study of the Liver (EASL), European Association for the Study of Diabetes (EASD) and European Association for the Study of Obesity (EASO). EASL-EASD-EASO clinical practice guidelines for the management of non-alcoholic fatty liver disease. J Hepatol. 2016 Jun;64(6):1388-1402. doi: 10.1016/j.jhep.2015.11.004. Accessed 4 Nov 2016. PMID: 27062661
  3. Iser D, Ryan M. Fatty liver disease - a practical guide for GPs. Aust Fam Physician. 2013 Jul;42(7):444-447. http://www.racgp.org.au. Accessed 4 Nov 2016. PMID: 23826593
  4. LaBrecque DR, Abbas Z, Anania F, et al. World Gastroenterology Organisation global guidelines: Nonalcoholic fatty liver disease and nonalcoholic steatohepatitis. J Clin Gastroenterol. 2014 Jul;48(6):467-473. doi: 10.1097/MCG.0000000000000116. PMID: 24921212
  5. National Institute for Health and Care Excellence. Non-alcoholic fatty liver disease (NAFLD): assessment and management. NICE. www.nice.org.uk. Jul 2016. Accessed 4 Nov 2016.
  6. Torres DM, Harrison SA. Nonalcoholic fatty liver disease. In: Feldman M, Friedman L, Brandt L, eds. Sleisenger and Fordtran’s gastrointestinal and liver disease. 10th: Saunders, an imprint of Elsevier Inc; 2016. 1428-1440. :1428-1440.
  7. Watanabe S, Hashimoto E, Ikejima K, et al. Evidence-based clinical practice guidelines for nonalcoholic fatty liver disease/nonalcoholic steatohepatitis. J Gastroenterol. 2015 Apr;50(4):364-377. doi: 10.1007/s00535-015-1050-7. Accessed 4 Nov 2016. PMID: 25708290
  8. Chalasani N, Younossi Z, Lavine JE, et al. The diagnosis and management of nonalcoholic fatty liver disease: Practice guidance from the American Association for the Study of Liver Diseases. Hepatology. 2018 Jan;67(1):328-357. doi: 10.1002/hep.29367. PMID: 28714183
  9. Crabb DW, Im GY, Szabo G, et al. Diagnosis and treatment of alcohol-related liver diseases: 2019 practice guidance from the American Association for the Study of Liver Diseases. Hepatology. 2019 Jul 17. doi: 10.1002/hep.30866. Accessed 16 Jan 2020. PMID: 31314133
  10. European Association for the Study of the Liver. EASL clinical practice guidelines: management of alcohol-related liver disease. J Hepatol. 2018 Jul;69(1):154-181. doi: 10.1016/j.jhep.2018.03.018. Accessed 16 Jan 2020. PMID: 29628280
  11. Kanazawa I, Tanaka K, Sugimoto T. DPP-4 inhibitors improve liver dysfunction in type 2 diabetes mellitus. Med Sci Monit. 2014 Sep;20:1662-1667. doi: 10.12659/MSM.890989. PMID: 25228119
  12. Mashitani T, Noguchi R, Okura Y, et al. Efficacy of alogliptin in preventing non-alcoholic fatty liver disease progression in patients with type 2 diabetes. Biomed Rep. 2016 Feb;4(2):183-187. doi: 10.3892/br.2016.569. PMID: 26893835
Editor's Recommendations
Special Reports